Association of the MMP-3 5A/6A gene polymorphism with multiple sclerosis in patients from Serbia

Journal of the Neurological Sciences

Volumn 267, Issue 1-2, 2008, Pages 62-65

  Djurić, Tamara ^a   Živković, Maja ^a   Stanković, Aleksandra ^a   Dinčić, Evica ^b   Raičević, Ranko ^b   Alavantić, Dragan ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

Gene polymorphism; MMP 3; MSSS; Multiple sclerosis

Indexed keywords

STROMELYSIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SERBIA;

ADULT; CENTRAL NERVOUS SYSTEM; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; YUGOSLAVIA;

EID: 39149105944     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.09.037     Document Type: Article

References (28)

1. Compston A., and Coles A. Multiple sclerosis. Lancet 359 (2002) 1221-1231
2. Piccio L., Rossi B., Scarpini E., Laudanna C., Giagulli C., Issekutz A.C., et al. Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J Immunol 168 (2002) 1940-1949
3. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C., et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72 (1997) 155-161
4. Chandler S., Coates R., Gearing A., Lury J., Wells G., and Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201 (1995) 223-226
5. Woessner Jr. J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5 (1991) 2145-2154
6. Mun-Bryce S., Lukes A., Wallace J., Lukes-Marx M., and Rosenberg G.A. Stromelysin-1 and gelatinase A are upregulated before TNF-alpha in LPS-stimulated neuroinflammation. Brain Res 933 (2002) 42-49
7. Kanesaka T., Mori M., Hattori T., Oki T., and Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 77 (2006) 185-188
8. Kouwenhoven M., Ozenci V., Gomes A., Yarilin D., Giedraitis V., Press R., et al. Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes. J Autoimmun 16 (2001) 463-470
9. Maeda A., and Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55 (1996) 300-309
10. Ye S., Watts G.F., Mandalia S., Humphries S.E., and Henney A.M. Preliminary report: Genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 73 (1995) 209-215
11. Ye S., Erikson P., Hamsten A., Kurkinen M., Humpries S.E., and Henney A.M. Progression of coronary atherosclerosis is associated with common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 271 (1996) 13055-13060
12. Medley T.L., Kingwell B.A., Gatzka C.D., Pillay P., and Cole T.J. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 92 (2003) 1254-1261
13. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
14. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of New Agents in Multiple Sclerosis. Neurology 46 (1996) 907-911
15. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
16. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64 (2005) 1144-1151
17. Djuric T., Zivkovic M., Mecanin S., Stankovic A., and Alavantic D. Endothelial NOS G894T and MMP-3 5A/6A gene polymorphisms and hypertension in Serbian population. J Clin Lab Anal 19 (2005) 241-246
18. D'Souza C.A., and Moscarello M.A. Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope. Neurochem Res 31 (2006) 1045-1054
19. Ghilardi G., Biondi M.L., DeMonti M., Turri O., Guagnellini E., and Scorza R. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 33 (2002) 2408-2412
20. Mattey D.L., Nixon N.B., Dawes P.T., Ollier W.E., and Hajeer A.H. Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun 5 (2004) 147-149
21. Constantin A., Lauwers-Cances V., Navaux F., Abbal M., van Meerwijk J., Mazieres B., et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum 46 (2002) 1754-1762
22. Goertsches R., Comabella M., Navarro A., Perkal H., and Montalban X. Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis. J Neuroimmunol 164 (2005) 140-147
23. Zhu C., Odeberg J., Hamsten A., and Eriksson P. Allele-specific MMP-3 transcription under in vivo conditions. Biochem Biophys Res Commun 348 (2006) 1150-1156
24. Yong V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 6 (2005) 931-944
25. Muir E.M., Adcock K.H., Morgenstern D.A., Clayton R., von Stillfried N., Rhodes K., et al. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Mol Brain Res 100 (2002) 103-117
26. Demestre M., Wells G.M., Miller K.M., Smith K.J., Hughes R.A., Gearing A.J., et al. Characterisation of matrix metalloproteinases and the effects of a broad-spectrum inhibitor (BB-1101) in peripheral nerve regeneration. Neuroscience 124 (2004) 767-779
27. Samnegard A., Silveira A., Tornvall P., Hamsten A., Ericsson C.G., and Eriksson P. Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 259 (2006) 530-536
28. Liu P.Y., Li Y.H., Chan S.H., Lin L.J., Wu H.L., Shi G.Y., et al. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am J Cardiol 98 (2006) 1012-1017